0001209191-23-058973.txt : 20231218
0001209191-23-058973.hdr.sgml : 20231218
20231218164723
ACCESSION NUMBER: 0001209191-23-058973
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231214
FILED AS OF DATE: 20231218
DATE AS OF CHANGE: 20231218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nagendran Sukumar
CENTRAL INDEX KEY: 0001665124
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 231494425
MAIL ADDRESS:
STREET 1: C/O AVEXIS, INC., 2275 HALF DAY ROAD
STREET 2: SUITE 160
CITY: BANNOCKBURN
STATE: IL
ZIP: 60015
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-14
0
0001806310
Taysha Gene Therapies, Inc.
TSHA
0001665124
Nagendran Sukumar
C/O TAYSHA GENE THERAPIES, INC.
3000 PEGASUS PARK DRIVE, SUITE 1430
DALLAS
TX
75247
1
1
0
0
President and Head of R&D
0
Employee Stock Option (right to buy)
0.6989
2023-12-14
4
A
0
334005
0.00
A
2033-12-14
Common Stock
334005
334005
D
The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
/s/ Kamran Alam, Attorney-in-Fact
2023-12-18